Fresh analysis reveals that people who discontinue popular weight-loss injections like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who end traditional lifestyle regimens.
Published data in a leading medical journal points out that while obese people often shed substantial amounts of their body weight while on the medication, the mass comes back at an estimated rate of nearly a kilo each month once they quit.
"People purchasing such treatments must be informed of the potential of fast weight regain when the therapy ends," warns expert Dr. Susan Jebb.
Such speed of recovery implies a return to pre-treatment mass in about a year and a half.
Comparing Approaches
The research, which looked at dozens of trials involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with other pills.
Researchers emphasize that individuals who lose weight through dieting typically experience a less rapid weight regain—perhaps 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Nutrition scientists propose the mechanism of the jabs accounts for the amplified weight return.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production may cause the system to produce less of its own natural GLP-1, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' leads to appetite is unsuppressed, making overeating a significant risk."
An Ongoing Issue?
Medical guidelines advise the jabs for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Professionals contend that, given the significant potential of weight regain, the treatment is often long-term.
This perspective is reinforced by pharmaceutical companies, who state that the findings "highlight the long-term character of obesity," similar to managing diseases like diabetes.
User Accounts
Users who have come off the medication report a intense resurgence of appetite.
"It was like a trigger that goes on and you become extremely hungry," described one woman.
The struggle is worsened if individuals have not adopted sustainable dietary or behavioural changes during therapy.
Significant Interest
Figures indicate that millions of adults in the UK have used these injections in the last 12 months, with desire remaining high.
- Adoption is more common among women than males.
- The middle-aged demographic shows the highest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
Finally, experts emphasize that while these medications are potent tools for shedding pounds, they are not a magic solution and long-term success hinges on integrated behavioural support.
